0001437749-21-014391.txt : 20210712 0001437749-21-014391.hdr.sgml : 20210712 20210609114743 ACCESSION NUMBER: 0001437749-21-014391 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474671999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 CORRESP 1 filename1.htm mbrx20210609_corresp.htm

 

 

June 9, 2021

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Attention: Ada D. Sarmento

 

  Re: Moleculin Biotech, Inc.
    Registration Statement on Form S-3
    Registration No. 333-256627

 

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on June 11, 2021, or as soon thereafter as possible on such date.

 

 

  Very truly yours,  
     

 

Moleculin Biotech, Inc.

 

 

 

 

 
       

 

 

 

 

 

By:

/s/ Jonathan Foster

 

 

 

Name: Jonathan Foster

 

 

 

Title: Chief Financial Officer